The hydrolysis of ceramides in yeast is catalysed by the alkaline ceramidases Ypc1p and Ydc1p, two highly homologous membrane proteins localized to the ER (endoplasmic reticulum). As observed with many enzymes, Ypc1p can also catalyse the reverse reaction, i.e. condense a non-esterified fatty acid with PHS (phytosphingosine) or DHS (dihydrosphingosine) and thus synthesize ceramides. of an acylceramide. The synthesis of acylceramide could also be monitored using fluorescent NBD (7-nitrobenz-2-oxa-1,3-diazole)-ceramides as an acceptor substrate for microsomal assays. The Lro1p-dependent transfer of oleic acid on to NBDceramide was confirmed by high-resolution Fourier transform and tandem MS. Immunopurified Lro1p was equally able to acylate NBD-ceramide. Lro1p acylates NBD-ceramide by attaching a fatty acid to the hydroxy group on the first carbon atom of the longchain base. Acylceramides are mobilized when cells are diluted into fresh medium in the presence of cerulenin, an inhibitor of fatty acid biosynthesis.
INTRODUCTION
Sphingolipids are essential structural components of cell membranes that also have messenger functions regulating the proliferation, survival and death of cells. The yeast sphingolipids consist of LCBs (long-chain bases), LCB-1-phosphates, ceramides, IPCs (inositolphosphorylceramides) and their mannosylated derivatives [1] . Sphingolipid synthesis begins in the ER (endoplasmic reticulum), where serine palmitoyltransferase uses serine and a fatty acyl-CoA to make 3-oxo-sphinganine, which is then converted into DHS (dihydrosphingosine; sphinganine). DHS is then hydroxylated at C4 by Sur2p yielding its 4-hydroxy derivative PHS (phytosphingosine; 4-hydroxysphinganine). Ceramides are made in the ER, whereas the biosynthesis of IPCs and more complex sphingolipids occurs in the Golgi [2] . Thus ceramide is an intermediate in the formation of complex sphingolipids. In mammalian cells, many reports have documented the important role of ceramides as signalling molecules [3] .
In the yeast Saccharomyces cerevisiae the biosynthesis of ceramide is mainly achieved by the acyl-CoA-dependent ceramide synthase LAG1 and its close homologue LAC1, formerly known as longevity assurance genes [4, 5] . Ceramides then can follow any one of several pathways, as indicated in Figure 1 . Ceramides can also be hydrolysed by Ypc1p and Ydc1p, two alkaline ceramidases that display more then 50 % of homology over their entire amino acid sequence and reside in the ER, where Lag1p and Lac1p are also localized. Ypc1p catalyses, in vitro and in certain instances in vivo, the reverse reaction, i.e. the condensation of non-esterified fatty acids with PHS or DHS [6] . Ydc1p, in contrast with Ypc1p, has been shown to hydrolyse only DHS-containing ceramides and exhibits only very weak reverse activity in vitro, but seems to be able to work in the reverse direction in vivo [5, [7] [8] [9] .
Like many organisms, yeast store neutral lipids in the form of LDs (lipid droplets). Synthesis of neutral lipids and thus LD biogenesis in yeast is mediated by two acylCoA:sterol acyltransferases, Are1p and Are2p, and by Lro1p and Dga1p, which acylate DAG (diacylglycerol) to produce TAG (triacylglycerol). All of these enzymes are present in the ER, except for Dga1p which has a much higher specific activity in LDs than the ER [10] [11] [12] . LRO1 accounts for the major part of TAG biosynthesis in exponentially growing cells and is homologous with the mammalian LCAT (lecithin cholesterol acyltransferase) [13, 14] . Lro1p transfers a fatty acid from the sn-2 position of PE (phosphatidylethanolamine) or PC (phosphatidylcholine) on to DAG, whereas Dga1p transfers the fatty acid from acylCoA on to DAG [10, [13] [14] [15] . Neutral lipid synthesis and storage are dispensable for the viability of S. cerevisiae because an are1 are2 dga1 lro1 quadruple mutant is viable, makes no storage lipids and lacks detectable LDs [14, 16] .
In the present paper we report on the enzymatically mediated acylation of ceramides, a process which physiologically may allow for ceramide storage or detoxification.
EXPERIMENTAL

Strains, growth conditions and materials
S. cerevisiae strains used are listed in Table 1 and plasmids used are listed in Table 2 . Mutant strains were generated using standard methods for crossing of single mutants, for plasmid transfection or gene disruption using deletion cassettes generated As BY4742 but also containing pRS415 The present study WT.YPC1 (FBY5215) As BY4742 but also containing pYPC1-LEU2 The present study lro1 .YPC1 (FBY5219) As BY4742, but lro1::kanMX and also containing pYPC1-LEU2 The present study lro1 .YPC1.LRO1 (FBY5277) As BY4742, but lro1::kanMX and also containing pYPC1-URA3 and pLRO1-LEU2 The present study ypc1 ydc1 .vector (FBY5322)
MAT α can1 ::STE2pr-Sp_his5 lyp1 his3 1 leu2 0 ura3 0 met15 0 ypc1::LEU2 ydc1::natMX containing pNP302
The present study ypc1 ydc1 .YPC1 (FBY5321)
MAT α can1 ::STE2pr-Sp_his5 lyp1 his3 1 leu2 0 ura3 0 met15 0 ypc1::LEU2 ydc1::natMX containing pYPC1-URA3 The present study are1 are2 lro1 .DGA1 (RSY3292)
As BY4742 but are1::kanMX are2::kanMX trp1::URA3 lro1::loxP GAL1 UAS -GFP-DGA1::HIS3
[12] are1 are2 dga1 .LRO1 (RSY3202)
As BY4742 but are1::kanMX are2::kanMX trp1::URA3 dga1::loxP GAL1 UAS -GFP-LRO1::HIS3 R. Schneiter are1 lro1 dga1 .ARE2 (RSY3492)
As BY4742 but lro1::kanMX dga1::loxP are1::loxP GAL1 UAS -ARE2::HIS3 R. Schneiter scs7 BY4742, but scs7::kanMX EUROSCARF isc1
BY4742, but isc1::kanMX EUROSCARF are1 are2 dga1 .LRO1.DGA1 (RSY4360) As BY4742 but are1::kanMX are2::kanMX trp1::URA3 dga1::loxP GAL1 UAS -LRO1::TRP1 containing pGAL1-GFP-DGA1-URA3 R. Schneiter
Figure 1 Ceramide biosynthesis and utilization in yeast
The various metabolic pathways generating and consuming ceramides are shown. Gene names are in italic. The novel pathway generating acylceramides described in the present paper is in bold. 12 -NBD-PHS and C 6 -NBD-DHS; NBD is 7-nitrobenz-2-oxa-1,3-diazole) and fatty acyl-CoAs were from Avanti Polar Lipids. C 6 -NBD-sphingosine was from Invitrogen. Monomethylamine (33 % in ethanol) was from Fluka. Dynabeads ® -Protein G was from Invitrogen. Zymolyase-20T (Arthtrobacter luteus) was from Seikagaku Biobusiness. Mouse monoclonal anti-GFP (green fluorescent protein) antibodies were from Roche Diagnostics. The anti-mouse IgG-peroxidase conjugate was from Sigma.
Construction of plasmids
To construct plasmids containing YPC1, the open reading frame was amplified by PCR using the oligonucleotides 5 -CCT-GGGATCCATGGGAATATTTCGTTGGAACTATCC-3 and 5 -CGCCGCGGCCGCTTACTTCTCCTTTTTAACTTC-3 and genomic DNA from WT (wild-type) BY4742 cells. PCR products were doubly digested with NotI and BamHI and ligated into the similarly digested pNP308 or pNP302 vectors to generate pYPC1-LEU2 and pYPC1-URA3. DNA sequencing of inserts confirmed the correct sequence of YPC1.
Protein analysis
Proteins were extracted by mild alkali treatment and subsequent boiling of cells in a standard electrophoresis loading buffer [17] . Proteins were resolved by SDS/PAGE and detected by Western blotting using standard procedures.
Mass spectrometric lipid analysis
Microsomes were extracted with chloroform/methanol [2:1 (v/v)] [18] . Lipid extracts were analysed in negative-ion mode by direct infusion MS using an LTQ Orbitrap XL mass spectrometer equipped with the automated nanoflow ion source Triversa NanoMate (Advion Biosciences) [18] . C 6 -NBD-DHS and its acyl-derivatives were detected by high-resolution FT-MS (Fourier transform MS) using a target mass resolution of 100 000. In addition, the identity of detected C 6 -NBD-DHS and acyl-derivatives was confirmed by ion-trap MS/MS (tandem MS) analysis.
Metabolic labelling of cells with [
14 C]serine, lipid extraction, mild base treatment and TLC Cells were grown in synthetic minimal medium. Then 3.0 D 600 units of exponentially growing cells (3 ml of a culture having a D 600 of 1.0) were harvested and resuspended in 250 μl of the same medium supplemented with 10 μg/ml CHX. After 10 min of pre-incubation, 4 μCi of [ 14 C]serine was added and cells were incubated for 40 min at 30
• C. Then the samples were diluted with 750 μl of fresh minimal medium supplemented with CHX and labelling was continued for a further 120 min. Labelling was terminated by adding sodium azide and sodium fluoride (10 mM final concentrations) and chilling cells on ice. Cells were resuspended in chloroform/methanol [2:1 (v/v)] and broken with glass beads in the cold. The extract was kept apart and the pellet was re-extracted sequentially with chloroform/methanol [1:1 (v/v)] and ethanol/water/diethyl ether/putridine/25 % ammonium hydroxide (15:15:5:1:0.018, by vol.), which achieves quantitative extraction of all complex sphingolipids [19] . Extracts were combined and solvent was evaporated under vacuum in a rotary evaporator. Incorporation into lipids usually amounted to 5 % of radioactivity added. Where indicated, lipids were subjected to mild base hydrolysis with sodium hydroxide or MMA (monomethylamine). For this, lipids were resuspended in 200 μl of chloroform/methanol/water (10:10:3, by vol.), 40 μl of 0.6 M sodium hydroxide in methanol (final concentration of 0.1 M) was added, and samples were incubated for 1 h at 37
• C. Hydrolysis was stopped with 40 μl of 0.8 M acetic acid in methanol. Control samples were incubated on ice and at the end of the incubation supplemented with 40 μl of 0.8 M acetic acid plus 40 μl of 0.6 M sodium hydroxide. The desalted lipids were resolved by ascending TLC on silica gel plates. Alternatively, lipids were resuspended in 400 μl of MMA (33 % in ethanol) or, as a negative control, in methanol, and incubated at 53
• C for 1 h. Then, solvents were evaporated under vacuum. All lipids were resolved by ascending TLC on silica gel plates after having been desalted by Folch partitioning as described previously [20] . Unless indicated otherwise, extracts of microsomes were developed with solvent 1 (chloroform/methanol/25 % ammonium hydroxide, 9:2:0.5, by vol.) and extracts from metabolically labelled cells were developed with solvent 2 (chloroform/methanol/2 M ammonium hydroxide, 40:10:1, by vol.). When the untreated and deacylated lipid extract was run side by side, material from an equivalent number of cells was spotted, whether we analysed extracts from metabolic labellings or microsomal labelling reactions (see below). Radioactivity was detected and quantified by one-and two-dimensional radioscanning using a Berthold radioscanner and visualized by fluorography or radioimaging using the Bio-Rad Molecular Imager FX. Unless otherwise stated, radioactivity in individual spots was given as the percentage of total radioactivity detected by radioscanning in the corresponding lane, except for acylceramides. In the case of acylceramides, the counts of residual mild-base-resistant lipid co-migrating with acylceramides, as well as of an occasional trace of material co-migrating with fatty acids, were deducted from the acylceramide signal as follows:
Percentage of acylceramides = (acylceramide untreated − [acylceramide deacylated + fatty acid deacylated]/total counts untreated) × 100.
Preparation of microsomes
Microsomes were prepared from yeast cells grown in synthetic complete media. Briefly, as described previously [6] , cells were homogenized in a lysis buffer containing 25 mM Tris/HCl (pH 7.4), 1 mM PMSF and Roche protease inhibitor cocktail. Unbroken cells and cell debris were removed by centrifugation at 500 g for 5 min. The membrane fraction was sedimented by centrifuging the supernatant at 16 000 g for 40 min at 4
• C. The microsomes were resuspended in assay buffer A containing 25 mM Tris/HCl (pH 8.0), 5 mM CaCl 2 and 1 mM PMSF. In most experiments, boiled microsomes (100
• C for 10 min) were used as a negative control. Protein concentrations were determined using Bradford reagent (Bio-Rad Laboratories).
Microsomal assay of reverse ceramidase using [ 3 H]palmitate
The reverse ceramidase activity was measured as described previously [21] Microsomal assays using NBD-ceramides NBD-containing ceramides (C 12 -NBD-PHS, C 6 -NBD-DHS or C 6 -NBD-sphingosine) were bound to BSA using an established procedure [22] , which was modified as follows. For ten standard reactions, 100 nmol of NBD-ceramide were dissolved in 20 μl of ethanol and added to 200 μl of buffer A containing 40 mg/ml of fatty-acid-free BSA giving an NBD-ceramide to BSA molar ratio of 1:1. The solution was incubated on a wheel at 4
• C for 2 h. Microsomal pellets were dissolved in buffer A supplemented with 10 mg/ml of fatty-acid-free BSA, the final concentration of microsomal protein being 5.0 mg/ml. The reactions were initiated by adding 50-100 μg of microsomes to 10 nmol of NBD-ceramide in a final volume of 50 μl containing 10 mg/ml BSA. Reaction mixtures were incubated at 30
• C for 2 h and then stopped by adding 300 μl of chloroform/methanol [2:1 (v/v)]. Lipids were extracted, treated or not with mild base, desalted and resolved by TLC. Products of NBD-ceramide conversion were identified as fluorescent bands and quantified with a FluorChem 8900 fluorescence detector (Witec).
Immunopurification of Lro1p-GFP on Dynabeads ® -Protein G RSY3202 cells were grown on YPG media. Cells were collected, treated with zymolyase and spheroplasts were lysed with a Dounce homogenizer in buffer B [20 mM Hepes (pH 6.8), 0.2 M sorbitol, 50 mM potassium acetate, 2 mM EDTA and protease inhibitors]. Microsomes were sedimented by centrifugation at 16 000 g for 30 min at 4
• C and solubilized in buffer B with 0.5 % Triton X-100 for 30 min on ice whereupon non-solubilized material was removed by centrifugation. Next, 4 μg of mouse anti-GFP antibodies were bound to 50 μl (1.5 mg) of Dynabeads and the washed beads were incubated with 500 μg of solubilized microsomal protein for 30 min at room temperature (25 • C) on a rotating wheel. Beads were sedimented using a magnet, the supernatant containing non-bound proteins was removed and the beads were washed three times with 0.5 % Triton X-100 in PBS using magnetic sedimentation. Acylceramide synthesis was measured in a final volume of 90 μl for 2 h at room temperature. The assay contained buffer A, BSA (10 mg/ml), PC (450 μM), C 6 -NBD-DHS (50 μM), a final concentration of 0.5 % Triton X-100 and 20 μl of Dynabeads-Lro1p-GFP conjugate or supernatant containing non-bound proteins. For protein determination, purified Lro1p-GFP was eluted from beads at pH 2.5.
RESULTS
In vitro microsomal assay of ceramide synthase activity reveals Lro1p-dependent ceramide esterification
As described previously [6] , reverse ceramidase activity of Ypc1p can be measured by incubating microsomes with [ ceramides is higher when DHS is used as a substrate than when PHS is used ( Figure 2A ) and the reaction is much faster when YPC1 is overexpressed ( Figure 2A , lanes 1 and 2 compared with lanes 4 and 5, and Figure 2B ). (Microsomes from Ypc1p-overexpressing cells actually represent an easy and cheap way to generate radiolabelled ceramides.) The reverse ceramidase assay invariably also generated a lipid, which migrated faster than ceramides, pointing to its higher hydrophobicity as compared with ceramides (marked with an asterisk in Figure 2A ). We will show below that this species is likely to be a 1-O-acylated ceramide. O-acylated ceramides, as well as ceramides, did not appear when boiled microsomes were used ( Figure 2A , lanes 3, 6, 9 and 12). The putative acylceramides were scraped off the TLC plate and treated with sodium hydroxide for saponification ( Figure 2C ). Upon mild base hydrolysis the presumed acylceramides α and γ , generated using either DHS or PHS as substrates, yielded the corresponding ceramides (lanes 3, 4, 7 and 8); the ceramides themselves (β and δ) remained stable in the presence of sodium hydroxide (lanes 5, 6, 9 and 10), in agreement with the idea that the lipids marked with an asterisk in Figure 2 (A) are acylceramides.
Acylceramide had previously been shown to be made by mammalian cells when microsomes were incubated with N-acetyl- [ 3 H]sphingosine. The enzyme catalysing the synthesis of O-acylceramide in mammals was identified as LPLA2, a soluble lysosomal enzyme working mainly as an acid PLA 2 (phospholipase A 2 ), but able to also use ceramide rather than water as an acceptor substrate [23] . A BLAST search showed that its closest homologue in S. cerevisiae is Lro1p. Indeed, the synthesis of acylceramides was strongly reduced in lro1Δ cells, suggesting that LRO1 deletion abolished ceramide acylation (Figure 2A , lanes 7 and 8 compared with lanes 4 and 5). Moreover, the complementation of the lro1Δ mutant with a single copy plasmid bearing LRO1 under its native promoter completely rescued the acylation of ceramides (Figure 2A , lanes 10 and 11). We wondered whether the second yeast DAG acyltransferase, Dga1p, is also capable of catalysing the synthesis of acylceramide in vitro. To test for this we incubated microsomes of an lro1Δ strain overexpressing YPC1 with PHS and [ 3 H]palmitate as in Figure 2 (A), lane 8, in order to allow for the formation of labelled ceramides. At the end of the incubation, the reaction was supplemented with different acyl-CoAs as acyl donors for Dga1p and the incubation was continued for a further 1 h (Supplementary Figure S1 at http://www.BiochemJ.org/ bj/447/bj4470103add.htm). No acylceramide synthesis was detected in this experiment. Although Dga1p is able to acylate ceramides in vivo (see below), reasons for this negative in vitro experiment could be that Ypc1p and Dga1p reside in different subcompartments of the ER, which end up in different microsomes, i.e. that microsomes generating [ 3 H]ceramide did not contain enough Dga1p activity. Indeed, Dga1p activity is concentrated in LDs, whereas Lro1p is mainly present in the ER membrane [10, 13] (R. Schneiter, personal communication).
NBD-ceramides are acylated in vitro by Lro1p
To further support the idea that Lro1p is capable of O-acylating ceramides, we tested the capacity of microsomes to acylate fluorescent ceramides. Figure 3(A) demonstrates that up to 25 % of C 12 -NBD-PHS was acylated by microsomes in a 2 h assay, The indicated mutants were grown on glucose or galactose overnight. Microsomes were labelled as described above, but using C 6 -NBD-DHS, i.e. an NBD-C 6 fatty acid linked to the nitrogen of DHS. Microsomes of are1 are2 lro1 .DGA1 and are1 lro1 dga1 .ARE2 strains were additionally supplemented with 5 nmol of C 16:0 -CoA and C 18:1 -CoA respectively. b, boiled; Cer, ceramide; glc, glucose; gal, galactose; n, native. and the extent of this acylation was independent of the presence of Ypc1p in the ypc1Δydc1Δ background used in the present experiment ( Figures 3A and 3B) . However, when Ypc1p was present, we observed a faint signal, presumably corresponding to C 12 -NBD fatty acid, the product of the ceramidase activity of Ypc1p ( Figure 3A, lanes 1 and 5) . Qualitatively similar results were obtained with C 6 -NBD-DHS, having a shorter NBD-fatty acid and a different LCB ( Figure 3C , lanes 5 and 25, and Figure 4D ), whereby no ceramidase activity was detected, possibly because YPC1 was not overexpressed as in Figure 3 (A). Acylation, as well as hydrolysis of NBD-ceramides, were observed to a much lower degree when boiled microsomes were used in the reaction ( Figure 3A , lanes 3, 7, 11 and 15 compared with lanes 1, 5, 9 and 13, and Figure 3C ). The rate of C 12 -NBD-PHS hydrolysis by Ypc1p-containing microsomes in Figure 3 (A) amounted to approximately 1 % of total fluorescence (lanes 1 and 5), i.e. it was 6-fold faster than the hydrolysis by yeast microsomes strongly overexpressing human alkaline ceramidase [21] . Although we did not study the kinetics of the metabolism of NBD-ceramides in microsomes, it nevertheless is striking to observe that acylation of this artificial substrate by endogenous levels of Lro1p is 20-fold faster than its hydrolysis by the overexpressed Ypc1p ( Figure 3A , lanes 1 and 5), whereby the conditions used for acylceramide synthesis in Figure 3(A) are the same as the ones optimized for measuring Ypc1p-mediated ceramidase activity [6] . Mild base treatment also released approximately 1 % of the amide-bound NBD-C 12 fatty acids ( Figure 3A, lanes 4, 8, 12 and 16 compared with lanes 3, 7, 11 and 15).
To see which enzymes were responsible for NBD-ceramide acylation, we took advantage of are1 are2 lro1 .DGA1, are1 are2 dga1 .LRO1 and are1 lro1 dga1 .ARE2 strains, in which the endogenous DGA1, LRO1 or ARE2 gene is placed behind the GAL1-promoter respectively, while all other DAG-or sterol-acyltransferases are deleted. These mutants were cultured on glucose or galactose to repress the expression or induce the overexpression of LRO1, DGA1 or ARE2 respectively. (Are2p accounts for most of the sterol acyltransferase activity, when yeast cells grow in the presence of oxygen [24] .) Massive amounts of acylated C 6 -NBD-DHS were made by microsomes derived from cells overexpressing Lro1p after having been grown on galactose, much more than from cells grown on glucose ( Figure 3C , lanes 1 and 5). In contrast, overexpression of Are2p or of Dga1p did not result in significant microsomal ceramide acylation in the presence of acyl-CoA ( Figure 3C ).
Identification of the hydroxy group that is acylated by Lro1p
PHS has hydroxy groups on carbon atoms 1, 3 and 4, and DHS on carbon atoms 1 and 3. To decide whether ceramides are acylated on the carbon atom 1 or 3 of the LCB, we used a procedure previously employed by others [25] , which requires the use of ceramides containing sphingosine rather than DHS or PHS. Sphingosine is a dehydrogenated DHS with a 4 double bond ( Figure 4A ). We found that yeast microsomes efficiently acylate C 6 -NBD-sphingosine ( Figure 4B) . Acyl-C 6 -NBD-sphingosine and unreacted C 6 -NBD-sphingosine were scraped from a TLC plate and treated with DDQ (2,3-dichloro-5,6-dicyanobenzoquinone) [25] . DDQ oxidizes α-β-unsaturated alcohols to ketones. Thus an hydroxy group in the C3 position of sphingosine will be oxidized to a ketone group, unless it is acylated ( Figure 4A ). After treatment with DDQ, all of the C 6 -NBD-sphingosine was converted into corresponding 3-oxoforms, which have a higher TLC mobility, as described previously [25] (Figure 4C, lanes 1 and 2) . The same was true for acyl-C 6 -NBD-sphingosine ( Figure 4C, lanes 3 and 4) . Controls showed that C 6 -NBD-DHS and acyl-C 6 -NBD-DHS lacking the 4 double bond were not oxidized ( Figures 4D and 4E) . These results suggest that the microsomal ceramide esterification by Lro1p involves the hydroxy group on C1, not C3, of the LCB.
Lro1p transfers oleic acid on to NBD-ceramide
If Lro1p is the enzyme that acylates ceramides, we would expect that it transfers on to ceramides the same C 16 and C 18 fatty acids as to DAG. To test this, microsomes from WT cells were incubated with the ceramide analogue C 6 -NBD-DHS. Microsomes were subsequently extracted and analysed by high-resolution FT-MS and structural analysis by ion-trap MS/MS [18, 26] . FT-MS analysis detected a molecular ion with m/z 840.6215 in microsomes incubated with 1 and 2) . Lane 3 contains the C 6 -NBD-sphingosine as obtained from Invitrogen. Lipids were extracted and resolved by TLC. (C) Acyl-C 6 -NBD-sphingosine and C 6 -NBD-sphingosine from (B) were scraped off of the plate. Lipids were extracted from the silica and incubated for 48 h at 37 • C with or without 3 % DDQ in 40 μl of dioxane and then dried in a rotary evaporator as described previously [25] . The lipids were resuspended in 3 ml of chloroform/methanol [2:1 (v/v)] and 0.6 ml of 0.1 M sodium hydroxide was added. After vigorous shaking and brief centrifugation the lower layer (organic phase) was recovered and re-extracted twice with 2 ml of methanol/0.1 M sodium hydroxide [1:1 (v/v)] and twice more with 2 ml of methanol/water [1:1 (v/v)]. The lipids were resolved by TLC in chloroform/methanol/glacial acetic acid (90:1:9, by vol.) and then visualized by direct fluorescence using a FluorChem fluorescence detector. Oxidation of the C3 hydroxy group increases the mobility in this solvent system [25] . (D) The same experiment as in (B) was performed using 5 or 1 nmol of C 6 -NBD-DHS as a substrate. (E) Acyl-C 6 -NBD-DHS and C 6 -NBD-DHS of (D) were scraped and processed as in (C). (F) Lro1p-GFP was purified using an anti-GFP antibody. Equivalent aliquots of purified Lro1p-GFP bound to affinity beads (lanes 5-8) or of supernatant containing non-bound microsomal proteins were incubated with C 6 -NBD-DHS and PC for 2 h at room temperature. Lipids were extracted and separated on TLC as in (C). (G) Aliquots corresponding to equivalent amounts of starting material taken throughout purification were analysed by Western blotting using an anti-GFP antibody. b, boiled; n, native; Sph, sphingosine.
C 6 -NBD-DHS, but not in microsomes without the addition of C 6 -NBD-DHS or if microsomes had been boiled (Figures 5A-5D ). With a mass accuracy of 0.6 p.p.m., this molecular ion matches the identity of the acylceramide C 18:1 -C 6 -NBD-DHS (calculated m/z 840.6220). To confirm the identity of the C 18:1 -C 6 -NBD-DHS species we performed structural analysis by ion-trap MS/MS. The fragment ions derived from the ion with m/z 840.6215 could all be ascribed structural features in the intact acylceramide ion (Supplementary Figure S2 at http://www.BiochemJ.org/bj/447/bj4470103add.htm). Fragmentation thus confirms the synthesis of C 18:1 -C 6 -NBD-DHS in WT microsomes incubated with the precursor C 6 -NBD-DHS.
Next, to confirm that Lro1p is responsible for the synthesis of C 18:1 -C 6 -NBD-DHS, we tested whether increasing the expression level of the enzyme would increase the production of the acylceramide species. To this end, we monitored the production of C 18:1 -C 6 -NBD-DHS in microsomes from are1 are2 dga1 .LRO1 cells overexpressing LRO1 when cultured on galactose and in microsomes from low-levelexpressing cells cultured on glucose. We observed that the levels of C 18:1 -C 6 -NBD-DHS were massively increased when Lro1p was overexpressed (Figures 5E-5G ). In comparison, incubating microsomes from cells overexpressing DGA1 with C 6 -NBD-DHS did not yield significant amounts of C 18:1 -C 6 -NBD-DHS ( Figure 5H ).
PE and PC, which are the preferred substrates of Lro1p, most often carry C 18:1 at their sn-2 position [27] and, as shown in Figure 5 , this species seems to be attached by microsomes in an LRO1-dependent manner to C 6 -NBD-DHS. Taken together, these data support the idea that Lro1p is directly involved in transferring the fatty acid from PE or PC to ceramides.
Purified Lro1p can acylate NBD-ceramide in vitro
Lro1p-GFP was immunopurified from a strain with the chromosomal LRO1 tagged with GFP and placed under the GAL1 promoter ( Figure 4G ). Purified Lro1p-GFP was assayed in the presence of NBD-ceramide and PC as shown in Figure 4 (F). Calculating how much NBD-ceramide was transformed into acylceramide per microgram of protein during the assay demonstrated that the ceramide acylating activity was more than 800-fold enriched in the purified Lro1p-GFP fraction as compared with the immunodepleted supernatant. This again strongly suggests that the ceramide acylation reaction is carried out by Lro1p.
Ceramide acylation also occurs in living cells
Many processes taking place in vitro have no physiological correlate. Our calculations on the basis of concentrations of free ceramides in cells reported in the literature [4, 28] and on the specific activity of [ 3 H]palmitate added to microsomes of WT cells in assays of the type shown in Figure 2 (A) led us to conclude that we generated approximately 45-125 pmol of [ 3 H]C 16 -ceramide in microsomes that already contained a minimum of 50-100 pmol of C 26 -ceramides. This latter estimate is probably too low, since it can be expected that ceramides are more concentrated in ERderived Lro1p-containing microsomes than in the average cellular membrane. Also, when doing reverse ceramidase assays with WT.YPC1 microsomes as in Figure 2 (A), but not adding nonradioactive palmitate into the assays, so that only 14 pmol of of acylated ceramide ( Figure 6A, asterisk) . Mild base treatment led to the disappearance of part of this lipid and the appearance or increases of lipids considered to represent DHS-C 26 and PHS-C 26 -OH ( Figure 6A, lanes 7 and 8) . In many cases hydrolysis of these presumably acylated ceramides was incomplete, in others it was complete and we presently are not quite sure whether this hydrophobic lipid is heterogeneous, containing a mild-basesensitive and a mild-base-resistant component, or if it is not efficiently solubilized and therefore not efficiently hydrolysed.
As shown in Figure 6 (A), we labelled the living cells with at maximal speed only after 40 min, when ceramides had reached their maximal level but did not reach a plateau during the 2 h of labelling ( Figure 6B ). These data are compatible with a continuous acylation of part of the newly made ceramides. The same amounts of acylceramide were also observed, when ypc1Δydc1Δ cells were metabolically labelled, suggesting that the bulk of ceramides that are acylated in vivo are made by Lag1p and Lac1p (results not shown).
To see whether Lro1p, and possibly Dga1p or Are2p, were involved in making the very hydrophobic lipid species observed in Figure 6 (A), we again used the are1 are2 lro1 .DGA1, are1 are2 dga1 .LRO1 and are1 lro1 dga1 .ARE2 strains, in which the endogenous DGA1, LRO1 or ARE2 genes have been placed behind the GAL1-promoter respectively. These mutants have no LDs when grown on glucose, but induce LDs on galactose, indicating that expression of one of the three genes LRO1, DGA1 or ARE2 is sufficient to cause the appearance of LDs [12, 16] . Accordingly, these strains were grown on glucose or on galactose and then labelled with [ 14 C]serine along with WT cells (Figure 6C ). LRO1 and DGA1 overexpression was verified by Western blotting (Supplementary Figure  S3 at http://www.BiochemJ.org/bj/447/bj4470103add.htm) and allowed the cells to produce significant amounts of acylceramides ( Figure 6C , lanes 5-12, and Figure 6D ). ARE2 overexpression did not have any effect on the conversion of ceramide into its esters (results not shown), although its overexpression leads to a rapid appearance of LDs in an are1 are2 lro1 dga1 background [29] .
Significantly, all of these cell lines growing on glucose made very few acylceramides. This indicates that Lro1p and Dga1p are the only enzymes that can acylate the ceramide in living cells.
The quantification of the presumed acylceramides was always done by subtracting mild-base-resistant counts from total counts in the acylceramide band of the untreated sample (see the Experimental section). Calculated in this way, 7 % of the total incorporated radioactivity was present as acylceramide when DGA1 was overexpressed, and only 2 % when LRO1 was overexpressed ( Figure 6D ). In WT cells acylceramides amounted usually to approximately 2-5 % of total labelled lipids. In other words, a quarter of the total ceramides was usually esterified in WT cells ( Figure 6D ).
Characterization of [ 14 C]serine-labelled acylceramides
To obtain additional evidence for the biosynthesis of acylceramide in vivo we also labelled cells with [ 14 C]serine in the presence of myriocin, a specific inhibitor of the serine palmitoyl transferase catalysing the first step of sphingolipid biosynthesis. The synthesis of ceramides and acylceramide was strongly repressed by myriocin ( Figure 7A ). This further confirmed that the very hydrophobic labelled lipids observed after metabolic labelling with [
14 C]serine are indeed derived from sphingolipids, the biosynthesis of which requires LCB1. A similar reduction of ceramide and acylceramide biosynthesis was also observed in the thermosensitive lcb1-100 cells, labelled at 37
• C (results not shown).
Yeast ceramides either contain DHS or PHS, and their fatty acid can be either non-, mono-or bis-hydroxylated [30, 31] . The most abundant ceramide of yeast is phytoceramide containing an α-hydroxylated C 26:0 fatty acid (PHS-C 26 -OH) [18, 32] . To find out what ceramides became acylated, and to corroborate the idea that the most hydrophobic [
14 C]serine-labelled lipids in Figure 6 are acylceramides, such lipids were scraped off of the TLC plate and treated with mild base. Acylceramide from WT cells contained on average 40 % of a lipid running with PHS-C 26 -OH and 30 % of a lipid running with DHS-C 26 , the remainder being mild base resistant for unknown reasons (see above) ( Figure 7B and Table 3) . To see whether PHS-C 26 -type ceramides can also be acylated, we also labelled the scs7Δ strain, lacking the fatty acid hydroxylase [31] (Figure 7C ). Metabolic labelling of scs7Δ with [ 14 C]serine yielded a major band in the region of acylceramides, a large fraction of which was hydrolysed to lipids running with DHS-C 26 and PHS-C 26 , the latter being the main ceramide of this strain [31] . Thus the deletion of SCS7 does not prevent the biosynthesis of acylceramides and suggests that, although PHS-C 26 is not efficiently acylated in WT cells, the acyltransferases can utilize it in a scs7Δ background and that the resulting acylated PHS-C 26 is stable.
In view of the variability of the relative amounts of acylceramides observed in our experiments and in view of the known ability of yeast cells to secrete apolar lipids, such as acetylated cholesterol [33] , we tested whether yeast cells would secrete any acylceramide. However, when analysing the growth medium we could not detect any secreted acylceramides (Supplementary Figure S4A at http://www.BiochemJ.org/bj/447/ bj4470103add.htm).
Acylceramides can be mobilized when fatty acid synthesis is compromised
We also wondered whether an increased demand for fatty acids inducing the disappearance of LDs could lead to the hydrolysis of acylceramides. To test for this we utilized conditions in which high amounts of acylceramide were available for degradation. DGA1 and LRO1 were simultaneously induced in are1 are2 lro1 .DGA1.LRO1 cells in galactose-containing medium and cells were at the same time labelled with [ 14 C]serine for 16 h ( Figure 8A ). Chasing in fresh glucose medium, allowing for repression of DGA1 and LRO1, did not result in mobilization of acylceramides as compared with the simple continuation of the culture in the labelling medium ( Figure 8A , condition 2 compared with condition 1, and Figure 8B ). On the other hand, chasing with glucose medium supplemented with the fatty acid synthase inhibitor cerulenin led to the almost complete disappearance of acylceramides within 6 h ( Figure 8A , condition 3, and Figure 8B ). It is worth noting that, in Figure 8 , acylceramides were labelled in the absence of cycloheximide. Indeed, this drug enhances incorporation of [ 14 C]serine into lipids, but acylceramides are also made in its absence (Supplementary Figure S4B) .
We also tried to force the mobilization of acylceramides by inflicting a want of sphingolipids. For this, cells were labelled with [
14 C]serine for 12 h and chased for the indicated periods with non-radioactive serine in the presence of myriocin ( Figure 8C ). WT cells were used in this experiment as well as a strain deficient in Isc1p, the only enzyme in yeast able to hydrolyse IPCs [34, 35] . In isc1Δ mutants the pathway generating ceramides via the breakdown of complex sphingolipids is blocked (Figure 1) . TLC analysis did not show any significant mobilization of acylceramide during chase in both WT and isc1Δ ( Figure 8C columns). Indeed, the lipid profiles in WT and isc1Δ cells were very similar. Thus it appears that an acute lack of sphingolipids does not induce a mobilization of the ceramide moiety of acylceramides.
DISCUSSION
This present paper discusses the existence of a metabolic pathway in yeast, which previously had been characterized in mammalian cells. It allows ceramides to not only be processed for IPC biosynthesis or degradation via the ceramidases, but also to be transformed into acylceramides as shown in Figure 1 . Acylceramides, as judged by their physicochemical properties, could well be deposited in LDs, although this will have to be tested experimentally. At the moment it is not clear whether this pathway represents a mere detoxicification mechanism to protect cells from toxic amounts of ceramides or fatty acids [36] , or whether it also serves a storage purpose, similar to TAGs, which are mobilized to allow for rapid membrane biosynthesis when stationary phase cells are diluted into nutrient-rich media and resume growth [37] .
The acylceramides seem to be made by Lro1p and Dga1p, the former being the only enzyme showing activity in our microsomal in vitro system. In intact cells Dga1p also seems to be able to acylate ceramides, according to metabolic labelling experiments. It thus appears that Dga1p and Lro1p can utilize ceramide instead of DAG, but it is difficult to estimate the relative contributions of these enzymes from our experiments, because the demonstration that either enzyme can acylate ceramides in living cells was performed in cells overexpressing either Lro1p or Dga1p ( Figure 6C ). Dga1p and Lro1p were previously shown to have relaxed substrate specificity in that they can also use monoacylglycerol and long-chain alcohols as an acceptor substrate [38, 39] , although they cannot use ergosterol [16, 40] . It has been reported that in microsomal assays Lro1p uses PE and PC as donor substrates, transfers saturated, unsaturated and even the nonnatural polyunsaturated fatty acids groups and may transfer fatty acids also from the sn-1 position, albeit at an approximately 10-fold lower rate than from the sn-2 position; it can even use DAG as a donor substrate [15, 38] .
We were able to show that microsomes attach O-acyls to the position 1 of sphingosine-containing ceramides using DDQ oxidation (Figure 4) . We tried to confirm this result by testing whether ceramides lacking the hydroxy group on C1 or lacking the hydroxylated C1 atom altogether could still be acylated. For this we added to microsomes [ 3 H]C 16:0 plus 1-deoxysphinganine or 1-deoxymethylsphingosine, lacking the terminal OH-or OH-CH 2 -group of classical LCBs, but these LCB analogues were not recognized as substrates by Ypc1p, and no corresponding 1-deoxy-or 1-deoxymethyl- [ 3 H]ceramides were generated in our microsomal in vitro system (results not shown). Ypc1p also did not recognize 3-oxo-sphinganine (results not shown). Thus we could not confirm that the O-acylation of DHS-and PHS-containing ceramides occurs on C1 using these approaches.
In our TLC system the deacylation products of the invivo-generated acylceramides mainly ran at the positions of DHS-C 26 and PHS-C 26 -OH, whereas almost no material comigrating with PHS-C 26 -OH appeared upon deacylation of acylceramides of the scs7Δ mutant lacking fatty acid hydroxylase ( Figure 7C ). Although this suggests that Dga1p and Lro1p mainly acylate DHS-C 26 and PHS-C 26 -OH, other ceramides may run to the same position on TLC. For instance, the position in this TLC system of the previously described PHS-C 14 -OH species [32] is unknown. Clearly more studies are required to identify the exact nature of the ceramide species acylated in living cells.
Lro1p is the only yeast homologue of the mammalian LPLA2, the first and only other enzyme reported to acylate ceramides on C1 [23, 25, 41] . The enzyme is a group XV PLA 2 , and is a close homologue of the extracellular LCAT of high-density lipoproteins. Although LPLA2 seems to function predominantly as a lysosomal acid phospholipase, it can, as many phospholipases, also act as a transacylase in the presence of suitable acceptor substrates. As (donor) substrates it prefers PE and PC and, contrary to its name, can release fatty acids from both sn-2 and sn-1 positions [42] . The acceptor specificity of LPLA2 is broad, and many long-chain hydrocarbons possessing a primary alcoholic group can be used as substrates [23] . As far as ceramides are concerned, the best substrate in in vitro reactions was N-acetyl-sphingosine, and much less activity was found with N-octanoyl-or N-stearyl-sphingosine as substrates [25] . Whether LPLA2 in vivo uses conventional ceramides with fatty acids of 14-24 carbon atoms is not clear.
Lro1p, LCAT and PLAL2 are homologues and, according to the conserved domains database at NCBI (http://www.ncbi.nlm. nih.gov/cdd/), they all have numerous identities with the 377 residues long pfam02450 consensus sequence over its entire length. Lro1p, LCAT and LPLA2 all contain a catalytic serinehistidine-aspartate triad; the first two in addition also contain a serine lipase motif [VxL(I/V)GHSxG] [13, 43] . In analogy to LCAT and LPLA2, which are active extracellularly and in the lysosome respectively, the catalytic residues of Lro1p also lie outside the cytoplasm, namely in the ER lumen. Indeed, Lro1p consists of a type II integral membrane glycoprotein with a single transmembrane helix [44] . Ceramides and DAGs therefore need to reach the ER lumen in order to get access to its catalytic site.
Metabolic labelling with [ 14 C]serine suggests that some newly made ceramides may be channeled into acylceramide biosynthesis and that they can be remobilized in the presence of cerulenin (Figure 8 ). It is not clear at present what enzymes hydrolyse the O-acyl group of acylceramides, and also it cannot be decided whether cerulenin mobilizes acylceramides by activating certain hydrolases or whether the mobilization is simply due to the disappearance of LDs [12] . Disappearance of LDs might bring acylceramides into contact with ER-localized hydrolases. Whatever the mechanism, the fact that acylceramides remain stable in the absence of cerulenin but start to disappear in its presence ( Figure 8A , lanes 1 and 2 compared with lanes 5 and 6, and Figure 8B ) does suggest that acylceramide breakdown may somehow be regulated.
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